Product Code: RP-ID-10086031 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10086031
Market Overview:
Global Human Growth Hormones Deficiency (GHD) Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2030
"Human Growth Hormone (HGH) market by application (growth hormone deficiency, Turner syndrome, idiopathic short stature, Prader-Willi syndrome and other applications), distribution channels (hospitals and retail pharmacies, online pharmacies and other distribution channels) ) And geography (North America, Europe, Asia Pacific, Middle East and Africa, and South America). The report provides the value (in millions of U.S. dollars) for the aforementioned market segments.
The market size of the human growth hormone market in 2021 is estimated to be ~USD 6 billion and is expected to expand at a compound annual growth rate of 9% during the forecast period 2022-2030. Hamdy Elkarow et al. published in Frontiers of the Journal of Endocrinology in November 2020. Patients with reduced growth hormone secretion constitute a risk factor for the severity of COVID-19, and preventive measures for susceptible people need to be paid attention to.
In addition, patients with Prader-Willi syndrome may not show typical symptoms, such as high fever, or may have higher than normal pain thresholds, which may delay the diagnosis of COVID-19. The development of recombinant human growth hormone drugs, the increase in cases of pituitary dysfunction, and the increase in unauthorized use of human growth hormone. In humans, growth hormone deficiency occurs when the pituitary gland cannot synthesize a sufficient concentration of human growth hormone.
This defect is treated by subcutaneous injection of recombinant human growth hormone. A variety of genetic diseases such as Prader-Willi syndrome and Turner syndrome can also cause growth hormone deficiency, leading to delayed puberty and lower than average height. Turner syndrome, also known as congenital ovarian hypoplasia syndrome, occurs when a woman X chromosome is partially or completely missing. According to a research article published by Xiaoxiao Cui et al. in Intractable & Rare Diseases Research Journal 2018, Turner syndrome (TS) is a relatively common human chromosomal aberration that occurs in 1:2500 live births.
Human growth hormone helps stimulate regeneration, reproduction and growth. Increasing use of growth hormone and awareness of growth hormone, which helps to manage growth hormone deficiency, is driving the growth of the market. In addition, most companies are investing in research and development to develop a growth hormone that has fewer side effects and will become a long-acting hormone therapy. In addition, it is expected that the rapid development of new recombinant human growth hormone will promote the development of the human growth hormone market during the forecast period.
REPORT SCOPE :
According to the report scope, human growth hormone, also known as growth hormone, is a peptide hormone that stimulates growth, cell reproduction and cell regeneration. Human growth hormone (HGH) market by application (applications such as growth hormone deficiency, Turner syndrome, idiopathic short stature, Prader-Willi syndrome, etc.), distribution channels (hospitals and retail pharmacies, online pharmacies and other distribution channels) Subdivision. And geography (North America, Europe, Asia Pacific, Middle East, Africa and South America). The report provides the value (in millions of U.S. dollars) for the aforementioned market segments.
MAIN MARKET TRENDS:
Turner syndrome segment is expected to maintain a considerable market share during the forecast period. Turner syndrome is a rare chromosomal disease that affects women. It is characterized by partial or complete loss of one of the X chromosomes.
Symptoms of Turner syndrome include a wide neck and low or inconspicuous hairline, a tendency to high blood pressure, mild eye problems, ptosis, and hypothyroid glands. Serious illness caused by the COVID-19 virus. In addition, patients with Turner syndrome usually suffer from congenital heart disease, including the bicuspid aortic valve. Heart disease is an underlying disease that can cause serious complications of COVID-19.
According to a research article by Xiaoxiao Cui et al. Turner syndrome (TS), published in Intractable & Rare Disease Research 2018, is a relatively common type of human chromosomal aberration that occurs in 1:2500 live births. As Turner syndrome is associated with many heart-related complications, autoimmune diseases, mental health problems, hearing loss, infertility, and pregnancy complications, the demand for growth hormone therapy is increasing, which drives the development of the market.
Increased awareness of early diagnosis and treatment of Turner syndrome by various public and private organizations is expected to drive market growth. For example, non-profit organizations such as the British Turner Syndrome Support Association, the American Turner Syndrome Association, and the Turner Syndrome Foundation celebrate "Turner Syndrome Awareness Month" every February and launch a nationwide campaign to Spread awareness of the disease. In addition, increased research and development in the development of effective treatments for Turner Syndrome (TS) has shown a positive impact on market growth.
For example, according to research published in Intractable & Rare Diseases Research 2018, the next generation of treatments for Turner syndrome (TS) will be based on stem cells and regenerative medicine. Therefore, taking into account the above factors, the market is expected to witness significant growth during the forecast period.
NORTH AMERICA IS EXPECTED TO DOMINATE THE MARKET DURING THE FORECAST PERIOD:
The main factors driving the growth of the US market include increased R&D activities, favorable reimbursement policies, established medical infrastructure, major government initiatives, and increased awareness of health care. Prader-Willi According to data from the Research Foundation Registry in August 2020, among patients with Prader-Willi syndrome, COVID-19 has affected access to medical care and treatment due to COVID-19-related restrictions in the United States. In addition, restrictions related to COVID-19 have also affected temporary access to physical, professional, verbal, and psychological treatment.
Treatments related to Prader-Willi syndrome are reduced by 60-80%. According to a research article published in the Journal of Genes in 2019 by Jessica Bohonowych et al., Prader-Willi syndrome (PWS) is a rare genetic disease. It is estimated that there are approximately 10,000 to 20,000 living people in the United States. According to the American Academy of Pediatrics, growth hormone deficiency is a rare disease that affects fewer than 3,000 to 10,000 children in the United States.
In the United States, recombinant growth hormone has been widely used to treat chronic renal failure, growth hormone deficiency (GHD), gestational age or intrauterine growth retardation, Turner syndrome, Prader-Willi syndrome, and cachexia. These deficiencies and treatment methods are expected to drive market growth. For example, every year, the Alliance of International Organizations Supporting Endocrine Patients (ICOSEP) celebrates Childhood Awareness Day to spread awareness of the early diagnosis and treatment of growth hormone disorders.
The number of drugs being processed continues to increase. For example, in October 2019, Pfizer and its partner OPKO Health Inc. announced that their phase III study of the use of human growth hormone in prepubertal children, Somatrogon, has reached its major non-inferiority in daily growth hormone. end. Therefore, due to the above factors, North America is expected to record growth during the forecast period.
COMPETITIVE LANDSCAPE :
The human growth hormone market is moderately integrated, with a small number of participants controlling an important market share. In addition, there are multiple positive associations in the development of more effective and long-lasting human growth hormone subtypes. Some of the major market players include AnkeBio Co. Ltd, Eli Lilly and Company, Ferring BV, Novo Nordisk AS, Ipsen SA, Pfizer Inc., Genentech Inc. (Roche) and Teva Pharmaceutical Industries Ltd.
MAJOR PLAYERS :
AnkeBio Co. Ltd Eli Lilly and Company Ferring BV Novo Nordisk ASIpsen SA Analysis of major market players In February 2021, Pfizer launched a phase III clinical trial to evaluate growth hormone in a group of Japanese participants Effectiveness and safety with Prader-Willi syndrome (PWS).
In October 2020, Erasmus Medical Center launched a phase III clinical trial in cooperation with Pfizer, Prader-Willi Research Foundation and Prader-Willi Fonds, To evaluate the physical and mental health of growth hormone (Genotropin) treatment for adults 30 years of age and older with Prader-Willi syndrome.
"
Ascendis Pharma A/S, Novo Nordisk A/S, Versartis Inc., Opko Health Inc., Pfizer Inc.
Related Reports
Proof of Quality & Reliability
